FDA Warning To Skin Care Firm Shows Perils Of Cosmetics-To-OTC Transition
This article was originally published in The Tan Sheet
Executive Summary
FDA's warning letter saying skin care product firm MW Laboratories marketed unapproved new drugs illustrates the potentially perilous transition from offering cosmeceuticals to marketing OTC drugs
You may also be interested in...
FDA Cedes To Marketplace As Personal Care Sector Enforcer – Attorney
FDA is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading,” Arent Fox partner Georgia Ravitz suggests based on an uptick in consumer class actions targeting personal care product claims and a lull in enforcement action in the sector since 2012.
FDA Cedes To Marketplace As Personal Care Sector Enforcer – Attorney
FDA is “letting the marketplace now scrutinize product label claims to determine whether they’re false or misleading,” Arent Fox partner Georgia Ravitz suggests based on an uptick in consumer class actions targeting personal care product claims and a lull in enforcement action in the sector since 2012.
Class-Actions Increasing As Fallout From Regulatory Action
Using marketing claims that overstep cosmetic boundaries can land firms in class-action suits that sap resources and drag on for years, attorneys noted at the ACI Legal, Regulatory and Compliance Forum on Cosmetics. Speakers provided examples and tips for staying out of court.